Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Recruiting now · Not applicable

Conditions studied: Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer

In brief

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Key facts

Study ID

NCT04612907

Run by

Umeå University

People needed

420

Starts

2022-10-31

Expected to finish

2032-09-30

Last updated by the study team

2024-02-28

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Signed Informed Consent
• Histological confirmed prostate cancer
• Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes
• baseline E-PROM

You may not qualify if…

• High burden metastatic prostate cancer including all with visceral mets.
• Unable to comply with study procedures.
• Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy
• Radiation treatment start later than nine months after the prostate cancer diagnosis.
• Severe micturition problems, IPSS > 20 ( International Prostate Symptom Score)

Where it is running

• Cancercenter University hospital of Umeå — Umeå, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.